Search

Your search keyword '"Kumar, Shaji K."' showing total 2,567 results

Search Constraints

Start Over You searched for: Author "Kumar, Shaji K." Remove constraint Author: "Kumar, Shaji K."
2,567 results on '"Kumar, Shaji K."'

Search Results

1. The clinical impact of acquired von Willebrand syndrome secondary to Waldenström macroglobulinemia: an underrecognized source of major bleeding events

2. Genetically determined telomere length in monoclonal gammopathy of undetermined significance, multiple myeloma risk and outcome

3. Phase II study of novel CXCR2 agonist and Plerixafor for rapid stem cell mobilization in patients with multiple myeloma

4. Real-life sensitivity of flow cytometry minimal residual disease assessment for plasma cell neoplasms

6. Impact of extramedullary multiple myeloma on outcomes with idecabtagene vicleucel

7. Outcomes of patients with multiple myeloma refractory to standard dose vs low dose lenalidomide

13. Correction: Value of bone marrow examination in determining response to therapy in patients with multiple myeloma in the context of mass spectrometry-based M-protein assessment

14. Retreatment of multiple myeloma with previously refractory drugs

15. Association of Thrombocytopenia With Disease Burden, High-Risk Cytogenetics, and Survival in Newly Diagnosed Multiple Myeloma Patients Treated With Novel Therapies

16. Identification of novel genetic loci for risk of multiple myeloma by functional annotation

19. Muscle and fat composition in patients with newly diagnosed multiple myeloma

20. Comparison of daratumumab-based regimens as second-line therapy in relapsed/refractory multiple myeloma

21. Long-term outcomes of allogeneic stem cell transplant in multiple myeloma

23. Utility of flow cytometry screening before MRD testing in multiple myeloma

26. Defining drug/drug class refractoriness vs lines of therapy in relapsed/refractory multiple myeloma

28. Cross center single-cell RNA sequencing study of the immune microenvironment in rapid progressing multiple myeloma

29. Impact of cytogenetic abnormalities on the risk of disease progression in solitary bone plasmacytomas

31. Value of bone marrow examination in determining response to therapy in patients with multiple myeloma in the context of mass spectrometry-based M-protein assessment

32. Outcomes of patients with primary refractory multiple myeloma in the era of triplet and quadruplet induction therapy

34. Impact of second primary malignancy post–autologous transplantation on outcomes of multiple myeloma: a CIBMTR analysis

35. Response to COVID-19 Vaccination Post-CAR T Therapy in Patients With Non-Hodgkin Lymphoma and Multiple Myeloma

36. Outcomes after biochemical or clinical progression in patients with multiple myeloma

38. Phase 2 trial of ixazomib, cyclophosphamide, and dexamethasone for previously untreated light chain amyloidosis

40. Utility of PET/CT in assessing early treatment response in patients with newly diagnosed multiple myeloma

41. Graded Organ Response and Progression Criteria for Kidney Immunoglobulin Light Chain Amyloidosis.

42. Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group

44. Mortality trends in multiple myeloma after the introduction of novel therapies in the United States

50. Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial

Catalog

Books, media, physical & digital resources